This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-20 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
== See also == List of Lord Lieutenants of West Yorkshire List of High Sheriffs of West Yorkshire The Kingdom of Elmet West Yorkshire Urban Area West Yorkshire Metropolitan Ambulance Service West Yorkshire Regiment (The Prince of Wales's Own) List of ceremonial counties in England by gross value added Listed buildings in West Yorkshire
Thionyl chloride is a component of lithium–thionyl chloride batteries, where it acts as both the electrolyte and the positive electrode (in batteries: cathode) with lithium forming the negative electrode (anode). The overall discharge reaction is as follows:
Biosynthesis is chemical synthesis occurring in biological contexts. It most often refers to multi-step, enzyme-catalyzed processes where chemical substances absorbed as nutrients (or previously converted through biosynthesis) serve as enzyme substrates, with conversion by the living organism either into simpler or more complex products. Examples of biosynthetic pathways include those for the production of amino acids, lipid membrane components, and nucleotides, but also for the production of all classes of biological macromolecules, and of acetyl-coenzyme A, adenosine triphosphate, nicotinamide adenine dinucleotide and other key intermediate and transactional molecules needed for metabolism. Thus, in biosynthesis, any of an array of compounds, from simple to complex, are converted into other compounds, and so it includes both the anabolism and catabolism (building up and breaking down) of complex molecules (including macromolecules). Biosynthetic processes are often represented via charts of metabolic pathways. A particular biosynthetic pathway may be located within a single cellular organelle (e.g., mitochondrial fatty acid synthesis pathways), while others involve enzymes that are located across an array of cellular organelles and structures (e.g., the biosynthesis of glycosylated cell surface proteins).
The Iapetus continued to expand and during that time bacteria, algae, and many species of invertebrates flourished in the oceans, but there were no plants or animals on land. Then, during the middle Ordovician Period about 500 to 470 million years ago, the motion of the crustal plates changed, and the continents began to move back toward each other. The once-quiet Appalachian passive margin changed to a very active plate boundary when a neighboring Iapetus oceanic plate containing a volcanic arc collided with and began sinking beneath the North American craton. Volcanoes grew along the continental margin coincident with the initiation of subduction. Thrust faulting uplifted and warped older sedimentary rock laid down on the passive margin. As the mountains rose, erosion began to wear them down over time. Streams carried rock debris downslope to be deposited in nearby lowlands. The Taconic orogeny ended after about 60 million years, but built much of the land mass that is now New England and southwestward to Pennsylvania. The Taconic Orogeny was the second of four mountain building plate collisions that contributed to the formation of the Appalachians, culminating in the collision of North America and Africa (see Alleghanian orogeny).
== Peace == The Global Peace Index 2018, published by the Institute for Economics and Peace ranked Thailand 113 of 163 nations for overall level of peacefulness (1=most peaceful; 163=least peaceful). Other ASEAN nations ranked were: Singapore, 8; Malaysia, 25; Laos, 46; Indonesia, 55; Vietnam, 60; Cambodia, 96; Myanmar, 122; and Philippines, 137.
Sources: en.wikipedia.org
=== Corrections of defect and deformity === Cancer – The excision of cancerous nasal skin can cause the loss of skin and internal support cartilage; such resections (surgical removal) usually are via the Mohs' chemosurgical technique. After removing the cancerous tissues, the reconstructive rhinoplasty will provide skin coverage using either skin grafts or pedicle flaps, (see Nasal Reconstruction, Paramedian Forehead Flap). If the resection of the cancerous skin leads to losing the nose tip, cartilage grafts can be used for support, and to prevent long-term distortion consequent to the force of the contracture of scar tissue.
== Overview == NAD⁺ is a ubiquitous enzyme cofactor that functions as a carrier of hydride ions in metabolic oxidation-reduction reactions. It also serves as a source of activated adenosine monophosphate (AMP) for adenylation reactions and as a precursor of ADP-ribose. Because of NAD⁺'s essential role in cellular metabolism, bacteria must carefully regulate genes involved in both the de novo biosynthesis and salvage (recycling) of NAD⁺ and its many derivatives. Two classes of NAD riboswitches have been identified: NAD-I and NAD⁺-II.
The final push for independence of Poland took place on the ground in October–November 1918. Near the end of the war, Austro-Hungarian and German units were being disarmed, and the Austrian army's collapse freed Cieszyn and Kraków at the end of October. Lviv was then contested in the Polish–Ukrainian War of 1918–1919. Ignacy Daszyński headed the first short-lived independent Polish government in Lublin from 7 November, the leftist Provisional People's Government of the Republic of Poland, proclaimed as a democracy. Germany, now defeated, was forced by the Allies to stand down its large military forces in Poland. Overtaken by the German Revolution of 1918–1919 at home, the Germans released Piłsudski from prison. He arrived in Warsaw on 10 November and was granted extensive authority by the Regency Council; Piłsudski's authority was also recognized by the Lublin government.[b1] On 22 November, he became the temporary head of state. Piłsudski was held by many in high regard, but was resented by the right-wing National Democrats. The emerging Polish state was internally divided, heavily war-damaged and economically dysfunctional.
Balancing and buck passing are the main strategies for preserving the balance of power and preventing a potential hegemon's rise. Instead of balancing against an aggressor, some states instead choose to "pass the buck" whereby instead of taking action to prevent a potential rise, it will pass the responsibility on to another state. John Mearsheimer, a prominent offensive realist, claims that threatened states can take four measures to facilitate buck passing, including: seeking good diplomatic relations with the aggressor in the hope that it will divert its attention to the "buck-catcher"; maintaining cool relations with the buck-catcher so as not to get dragged into the war with the buck-catcher and as a result possibly increase positive relations with the aggressor; increasing military strength to deter the aggressive state and help it focus on the buck-catcher; and facilitating the growth in power of the intended buck-catcher. In the case that a state is an enemy with both the aggressor and the intended buck-catcher, a buck-passer can implement a bait and bleed strategy whereby the state causes two rivals to engage in a protracted war while the baiter remains on the sideline. This form of buck passing enables the state to increase in relative strength at the expense of the two rivals. Bloodletting, a further variant whereby a state does what it can to increase the cost duration of the conflict can further increase the buck-passer's relative power.
== Further reading == Altschul, SF (1991). "Amino acid substitution matrices from an information theoretic perspective". Journal of Molecular Biology. 219 (3): 555–65. doi:10.1016/0022-2836(91)90193-A. PMC 7130686. PMID 2051488. Dayhoff, M. O.; Schwartz, R. M.; Orcutt, B. C. (1978). "A model of evolutionary change in proteins". Atlas of Protein Sequence and Structure. 5 (3): 345–352. Eddy, SR (2004). "Where did the BLOSUM62 alignment score matrix come from?". Nature Biotechnology. 22 (8): 1035–6. doi:10.1038/nbt0804-1035. PMID 15286655. S2CID 205269887. Henikoff, S; Henikoff, JG (1992). "Amino acid substitution matrices from protein blocks". Proceedings of the National Academy of Sciences of the United States of America. 89 (22): 10915–9. Bibcode:1992PNAS...8910915H. doi:10.1073/pnas.89.22.10915. PMC 50453. PMID 1438297.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.